After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...

The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...

In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

The startup world begins 2025 on a decidedly more upbeat note than it did the previous year. The renewed optimism is in part ...

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in funding to support the development of its kidney disease pipeline.

When we introduced the Nasdaq IPO Pulse a year ago, we said it suggested that U.S. “IPO activity… should remain in an uptrend” as we headed into 2024. Then, when we introduced the Nasdaq ...

And that could happen sooner rather than later. As a result, Renaissance expects a banner year for IPOs, with an estimated volume range of 155 to 195 IPOs in 2025 and $40 billion to $55 billion in ...

The biggest IPO of 2024 was the $5.10 billion float by Lineage, the world's largest operator of cold-storage warehouses, in July. This has been the best year for U.S. initial public offering ...

It’s a slimmer number by comparison, but the amount of money raised by some companies was impressive: The Nasdaq had a banner year, with 171 IPOs raising $22.7 billion. And not all IPOs have ...